文献速递皮肤肿瘤

澳大利亚原位及薄浸润性黑色素瘤过度诊断的规模与医疗费用估算

Estimating the magnitude and healthcare costs of melanoma in situ and thin invasive melanoma overdiagnosis in Australia.
PubMed 文献 · Br J Dermatol · 2024-01-01

该研究利用澳大利亚全国常规收集数据,采用两种终身风险评估方法,估算2017年和2021年男性和女性中原位黑色素瘤及薄浸润性黑色素瘤(IA期)的过度诊断比例及诊断后一年的医疗费用,发现过度诊断比例逐年上升且造成显著经济负担。

要点

  • 2017年原位黑色素瘤过度诊断比例为67%-70%,2021年升至71%-76%。
  • 薄浸润性黑色素瘤过度诊断比例从2017年22%-29%升至2021年28%-34%。

核心结论

  • 黑色素瘤过度诊断在澳大利亚是日益严重的临床和公共卫生问题,并在过度诊断后一年内产生显著经济成本。

研究设计与样本

  • 研究使用澳大利亚全国常规收集数据,采用两种终身风险计算方法,分别估算2017年和2021年男性和女性中原位黑色素瘤及薄浸润性黑色素瘤(IA期)的过度诊断数量和费用。

主要发现

  • 2017年薄浸润性黑色素瘤过度诊断比例为22%-29%,2021年升至28%-34%,对应过度诊断病例数在2831例(95%CI 2726-2935)至3168例(95%CI 3058-3279)之间。

临床怎么用

  • 临床应关注黑色素瘤过度诊断问题,限制过度诊断可能避免不必要的医疗资源使用并改善医疗系统财务可持续性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Research suggests that a high proportion of melanoma in situ (MIS) may be overdiagnosed, potentially contributing to overtreatment, patient harm and inflated costs for individuals and healthcare systems. However, Australia-wide estimates of the magnitude of melanoma overdiagnosis are potentially outdated and there has been no estimation of the cost to the healthcare system. OBJECTIVES: To estimate the magnitude and cost of overdiagnosed MIS and thin invasive melanomas in Australia. METHODS: Using two different methods to calculate lifetime risk, we used routinely collected national-level data to estimate overdiagnosed MIS and thin invasive melanomas (stage IA) in Australia in 2017 and 2021, separately for men and women. We multiplied the number of overdiagnosed melanomas by the estimated annual cost of a MIS or thin invasive melanoma, to quantify the financial burden of melanoma overdiagnosis to the Australian healthcare system in the year following diagnosis. RESULTS: We estimated that 67-70% of MIS were overdiagnosed in 2017, rising to 71-76% in 2021, contributing to between 19 829 [95% confidence interval (CI) 19 553-20 105] and 20 811 (95% CI 20 528-21 094) cases of overdiagnosed MIS. In 2021, the estimated costs in Australia ranged between $17.7 million Australian dollars (AUD; 95% CI 17.4-17.9 million) and AUD$18.6 million (95% CI 18.3-18.8 million). We estimated that 22-29% of thin invasive melanomas were overdiagnosed in 2017, rising to 28-34% in 2021, contributing to between 2831 (95% CI 2726-2935) and 3168 (95% CI 3058-3279) overdiagnosed thin invasive melanomas. In 2021, the estimated costs from thin invasive melanoma overdiagnoses ranged between AUD$2.5 million (95% CI 2.4-2.6 million) and AUD$2.8 million (95% CI 2.7-2.9 million). CONCLUSIONS: Melanoma overdiagnosis is a growing clinical and public health problem in Australia, producing significant economic costs in the year following overdiagnosis. Limiting melanoma overdiagnosis may prevent unnecessary healthcare resource use and improve financial sustainability within the Australian healthcare system. Over-diagnosis of melanoma (a type of skin cancer) can happen when someone has a spot that looks like melanoma but would not have caused any problems if it had not been found. Estimates of stage 0 melanoma (also called ‘melanoma in situ’) over-diagnosis in Australia and the USA range between 45% and 85%. There have been no estimates of the costs associated with this. We used nationwide data to find out the extent and cost of stage 0 and stage IA (also called ‘thin invasive melanoma’) overdiagnosis in Australia. We first calculated the lifetime risk of a melanoma diagnosis in 2004, 2017 and 2021. Next, we estimated the proportion of melanomas that are over-diagnosed. We also calculated the cost of over-diagnosis. We estimated that 67% to 70% of stage 0 melanomas were over-diagnosed in Australia in 2017, rising to 71% to 76% in 2021. The proportion of over-diagnosed stage IA melanoma was 22% to 29% in 2017, rising to 28% to 34% in 2021. Over-diagnosed melanomas cost the Australian healthcare system approximately $21.6 million in 2021. Our study findings suggest that melanoma overdiagnosis is a growing problem in Australia. This problem results in significant economic costs.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Lindsay D, Bell KJL, Olsen CM, et al. Estimating the magnitude and healthcare costs of melanoma in situ and thin invasive melanoma overdiagnosis in Australia. Br J Dermatol. 2024. PMID: 39026390. doi:10.1093/bjd/ljae296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。